Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -87.87M | -88.74M | -87.12M | -77.95M | -78.06M |
| Total Depreciation and Amortization | 5.32M | 5.48M | 5.52M | 5.49M | 5.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.75M | 22.94M | 22.82M | 21.43M | 23.25M |
| Change in Net Operating Assets | -22.09M | -31.31M | -38.22M | -51.04M | -59.67M |
| Cash from Operations | -88.89M | -91.62M | -97.01M | -102.07M | -109.07M |
| Capital Expenditure | -574.00K | -823.00K | -1.95M | -2.49M | -3.11M |
| Sale of Property, Plant, and Equipment | 37.00K | 37.00K | 37.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.07M | 100.49M | 65.32M | 33.79M | -85.04M |
| Cash from Investing | 103.53M | 99.71M | 63.41M | 31.30M | -88.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 202.00K | 109.00K | 109.00K | 0.00 | 86.54M |
| Repurchase of Common Stock | -- | -- | -492.00K | -2.52M | -2.52M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -558.00K | -539.00K | -352.00K | -77.00K | -- |
| Cash from Financing | -356.00K | -430.00K | -735.00K | -2.60M | 84.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.28M | 7.66M | -34.33M | -73.36M | -113.22M |